Source Search Page

thumbnail favicon targetedonc.com > view

Updated Trial and Real-World Data Show Benefit of Ide-Cel for Multiple Myeloma

16+ hour, 57+ min ago — 

...Khan, MBBS, assistant professor in the division of hematology at... ...The Ohio State University Comprehensive Cancer Center – The James... ...This is the first of 2 articles based on this event. 2 Commerce Drive... ...Blood-Based MRD Testing In this episode of Targeted Talks, Ben Derman...

thumbnail favicon targetedonc.com > view

Ruxolitinib Cream Shows Effectiveness in Treating Cutaneous GVHD

1+ day, 6+ min ago — 

...Alina Markova, MD, FAAD Results from a phase 2 trial presented at... ...small group of patients with cutaneous graft-vs-host disease (GVHD... ...of Dermatology Service at Memorial Sloan Kettering Cancer Center... ..., MD, FAAD, director of Inpatient Consultative Dermatology, co-director...

thumbnail favicon targetedonc.com > view

Liso-cel Appears Effective in High-Risk Patients With MCL

2+ day ago — 

...Lia Palomba, MD Lisocabtagene maraleucel (liso-cel; Breyanzi) showed... ...according to findings from a subgroup analysis of the TRANSCEND NHL... ...Lia Palomba, MD, attending physician from Memorial Sloan Kettering... ...Cancer Center, in a presentation of the data....

thumbnail favicon targetedonc.com > view

Scordo on Model-Based ATG Dosing in Allo-HCT

1+ day ago — 

...Michael Scordo, MD, discusses the implications of a new approach... ...personalized dosing strategy for the drug antithymocyte globulin (ATG... ..., and cellular therapist at Memorial Sloan Kettering Cancer Center... .... 2 Commerce Drive Cranbury, NJ 08512...

favicon targetedonc.com > view

Utilization Challenges Hold Back the Adoption of Bispecific Therapies

1+ day ago — 

...experience setting up standard operating procedures in their cancer centers... ...consistent option in the treatment armamentarium for patients with cancer... ...According to a 2020 survey from the Association of Community Cancer... ...In an event moderated by Maribel Pereiras, PharmD, BCPS, BCOP, 46%...

thumbnail favicon targetedonc.com > view

Rationale and Study Design of CAPItello-291 in HR+ Advanced Breast Cancer

1+ day ago — 

...Hope Rugo, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss... ...rationale and study design for CAPItello-291 in HR+ advanced breast cancer... ...is now included in the NCCN Breast Cancer Panel guidelines at 2... ...In an interview with Targeted Oncology, Chirag Shah, MD, discussed...

thumbnail favicon targetedonc.com > view

Key Takeaways from CAPItello-291 in HR+ Breast Cancer

1+ day ago — 

...MD, and Rahul Gosain, MD, provide closing thoughts on key takeaways... ...Following a comprehensive review of CAPItello-291, Rohit Gosain,... ...is now included in the NCCN Breast Cancer Panel guidelines at 2... ...In an interview with Targeted Oncology, Chirag Shah, MD, discussed...

thumbnail favicon targetedonc.com > view

Immunotherapy-Based Regimen Efficacy/Safety Updates

2+ day, 19+ min ago — 

...Motzer, MD, examined the impact of the CheckMate 214 and CheckMate... ...Beyond the First-Line: Economides on Advancing Therapies in RCC In... ...placebo in patients with clear cell renal cell carcinoma. 2 Commerce Drive... ...Cranbury, NJ 08512...

thumbnail favicon targetedonc.com > view

Key Data from CAPItello-291 in HR+ Breast Cancer

1+ day ago — 

...in patients with HR+ breast cancer, highlighting progression-free... ...REM-001 Trial Begins for Cutaneous Metastatic Breast Cancer Treatment... ...is now included in the NCCN Breast Cancer Panel guidelines at 2... ...In an interview with Targeted Oncology, Chirag Shah, MD, discussed...

thumbnail favicon targetedonc.com > view

Adverse Event Data from CAPItello-291 in HR+ Breast Cancer

1+ day ago — 

...Focusing on the safety profile, the Oncology Brothers and Hope Rugo... ...management practices for patients with breast cancer.... ...is now included in the NCCN Breast Cancer Panel guidelines at 2... ...In an interview with Targeted Oncology, Chirag Shah, MD, discussed...

 


**Content is provided on an “as is” basis. 4Internet, LLC makes no commitments regarding the content. What you see here may not be accurate and should not be relied upon. The content does not necessarily represent the views and opinions of 4Internet, LLC. You use this service and everything you see here at your own risk.